Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer
Toshio Shimizu, Kazuto Nishio, Kazuko Sakai, Isamu Okamoto, Kunio Okamoto, Masayuki Takeda, Maiko Morishita, Kazuhiko Nakagawa
Topics & Concepts
ErlotinibMedicinePharmacokineticsTolerabilityPharmacologyLung cancerSurvivinAdverse effectEpidermal growth factor receptorErlotinib HydrochlorideInternal medicinePhases of clinical researchCancerChemotherapyCell death mechanisms and regulationLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers